BfArMBundesinstitut für Arzneimittel und Medizinprodukte (German: Federal Institute for Drugs and Medical Devices)
BfArMBachelor of Farming
Copyright 1988-2018, All rights reserved.
References in periodicals archive ?
The BfarM tender foresees around 10 tons in cannabis to be cultivated domestically over four years.
Abbreviations: CAM, complementary and alternative medicine; NCI, National Cancer Institute; BfArM, German Federal Institute for Drugs and Medical Devices; i.v., intravenously.
Ixodes holds an approved clinical protocol with the FDA as well as the approval for the clinical design with the German BfArM.
The court said the BfArM had to reconsider three of the requests that it had rejected.
TRIN Pharma GmbH (, specializing in the development of small molecule drugs for tumour treatment, has announced that BfArM, the German regulatory authority, has approved the start of a Phase I clinical trial of TRIN 2755 in solid tumours.
The German BfArM (Federal institute for drugs and medical products) follows this line with its recommendations, and the Japanese authorities have also recommended the avoidance of phthalate-containing PVC products in medical applications.
[2] Bundesinstitut fur Armeimittel and Medizinprodukte (BfArM), Bonn, Germany.
In June 2002, the German BfArM (Bundesamt fur Arzneimittel und Medizin-produkte/Federal Institute for Drugs and Medical Devices) was the first health authority to ban all kava-containing preparations on the basis of a revised benefit/risk ratio, after the occurrence of a few sever adverse events supposedly related to kava intake.
Finnish pharmaceutical company Orion Corporation said on Thursday (2 October) that it had decided to withdraw its marketing authorisation application concerning the heart failure drug Simdax from the review process of the German regulatory drug authority BfArM (Bundesinstitut fur Arzneimittel und Medizinprodukte).
Food and Drug Administration (FDA) and Germany's Federal Institute for Drugs and Medical Devices (BfArM) agree on the study design of the Phase 3 NEPTUNE trial, including the use of the Angelman syndrome-specific Clinical Global Impressions of Improvement (CGI-I-AS) as the primary efficacy outcome measure.